<DOC>
	<DOCNO>NCT01537068</DOCNO>
	<brief_summary>The investigator study new antidepressant medicine , desvenlafaxine , treatment people chronic depression . Desvenlafaxine ( trade name Pristiq ) approve FDA treatment major depression . The investigator test whether medicine also effective adult type chronic depression less severe major depression . This condition also know dysthymic disorder dysthymia . Chronic depression , last two year , often cause significant suffer impairment . In addition , investigator use MRI imaging , use magnetic signal make picture brain 's structure also function . The purpose MRI imaging study see whether chronic depression associate difference brain structure functioning , whether difference change medication placebo treatment . To test MRI scan do start study 12 week medication placebo treatment . Getting MRI image option participant study require . This study involve 6 12 week double-blind period half participant take new medication half take placebo ( inactive look-alike pill ) . After double blind phase , subject treat 12 week FDA-approved antidepressant medication . Assessments ( depressive symptom , social functioning , personality ) do study staff patient study start , study visit first 12 week , 24 week study .</brief_summary>
	<brief_title>Desvenlafaxine v . Placebo Treatment Chronic Depression</brief_title>
	<detailed_description>The investigator wish study acute efficacy 12 week double blind basis continue response open-label treatment week 24 follow-up . It important establish acute ( 12 week ) efficacy desvenlafaxine non-major chronic depression . Also , give non-major chronic depression definition chronic , important demonstrate benefit persist follow-up assessment ( 24 week ) ; clinically important try alleviate significant psychosocial morbidity associate disorder . The investigator believe study significant value treatment patient non-major chronic depression , add significantly remain extremely small scientific literature . The investigator would also like study effect desvenlafaxine brain structure function . Learning medication reduces symptoms teach u medication achieve outcome . Participants study opportunity participate MRI scan help understand mechanism desvenlafaxine effective . MRI scan do prior start clinical trial complete double blind clinical trial .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Dysthymic Disorder</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Male female outpatient 20 65 year age , inclusive Principal DSM5 diagnosis unipolar nonmajor Chronic Depressive Disorder ( include Major Depression partial remission , Major Depression , residual , Dysthymic Disorder , Depressive Disorder NOS ) Minimum 2 year duration current episode depressive disorder . Score 12 high Hamilton Depression Scale ( 24 item ) baseline Full remission depression past 24 month Current major depression diagnosis , psychotic illness Current risk suicide Drug alcohol abuse/dependence past 6 month Active medical illness Prior nonresponse desvenlafaxine Medical illness contraindicating use desvenlafaxine Current plan pregnancy study period</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Dysthymic disorder</keyword>
	<keyword>Dysthymia</keyword>
	<keyword>Chronic non-major depression</keyword>
	<keyword>Non-major chronic depression</keyword>
	<keyword>Chronic depressive disorder</keyword>
	<keyword>Antidepressant treatment</keyword>
</DOC>